Vaccinepris og sygefravær afgørende for omkostningseffektivitet af rotavirusvaccination
Dorte Gyrd-Hansen1 & Kim Rose Olsen2 1) Institut for Sundhedstjenesteforskning, Syddansk Universitet 2) GlaxoSmithKline Pharma A/S
Cost of vaccination and cost of sick leave are determinants of cost-effectiveness vaccination against rotavirus
Ugeskr Læger 2012;174(8):480-483
The literature on cost-effectiveness of oral vaccination against rotavirus infection in high-income European countries is assessed in order to show which parameters are important for evaluation results and recommendations on inclusion in child immunization programs. There is a high degree of variation in results due to variation in country specific incidence rates, unit costs and assumed price of the vaccination. A determining factor is whether only costs to the health care system are included or whether a broader approach to costing is applied. A Danish discussion on this issue is pivotal.